We have already applied the same conditions for simultaneous CD8+ and CD4+ T cell assessment (10 μg/mL EP on day 1 and 50 μg/mL EP to read-out) to monitor tumor antigen-specific T cells in cancer patients. This evidence concerns the gene CD8A and cancer.